NVL-655: Promising New Option in Pretreated, Drug-Resistant ALK-Mutated NSCLC
In the phase 1/2 ALKOVE-1 trial, the ALK-selective tyrosine kinase inhibitor (TKI) NVL-655 demonstrated promising safety and clinical activity in patients with heavily pre-treated ALK-positive non-small cell lung cancer ...
